Nature Reviews Rheumatology

Article	Citations
No benefit from adding MTX to ustekinumab	376
Bimekizumab effective across the axSpA spectrum	319
Genome-wide mutagenesis reported in systemic sclerosis	303
The role of the patient in rheumatology	234
Reply to ‘Potential benefit of anticoagulation in Behçet syndrome’	228
Rheumatic diseases on the rise	194
A role for TGFβ and EBV in MIS-C pathogenesis	191
Obexelimab reduces the risk of IgG4-RD flare	181
Biological and clinical roles of IL-18 in inflammatory diseases	180
SLC26A2 deficiency, matrix stiffness and mechanotransduction linked in osteoporosis	179
Osteoarthritis as a systemic disease	170
Towards better management of sterile bone inflammation	167
New drug formulation reduces bone loss	159
The value of comparative efficacy studies in informing rheumatology guidelines	158
The 2022 ACR vaccination guideline: a call-to-action	155
Appraising the evolving landscape of protease inhibition in osteoarthritis	154
MIS-C: myths have been debunked, but mysteries remain	151
Imbalance of threat and soothing systems in fibromyalgia: rephrasing an established mechanistic model?	141
FOXP3 splice variant is associated with autoimmune disease	137
Urchin-like nanoparticles for miRNA therapy of OA	136
Inflammation across tissues: can shared cell biology help design smarter trials?	132
Down syndrome: insights into autoimmune mechanisms	130
Addressing the challenge of global delays in diagnosis and treatment of systemic lupus erythematosus	130
Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician	128
Co-trimoxazole reduces mortality in anti-MDA5-DM	125

Publisher Correction: Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician	124
Rheumatic diseases and metabolism: where centre and periphery meet	116
Biologics in rheumatoid arthritis: a lifetime treatment or possibility of drug holidays?	115
Wnt-induced IGF1 drives OA	115
A direct link between SARS-CoV-2 and bone loss	114
Calprotectin tracks tocilizumab-treated RA	110
Fumarate drives interferon release in systemic sclerosis monocytes	105
S100A4 inhibition targets fibrosis in SSc	104
Low back pain is a growing concern	99
Fibroblast TGFβ drives treatment-refractory RA	96
Author Correction: Proposals for the rheumatological use of JAK inhibitors	94
COPA syndrome spans multiple organs but is defined by STING in the lung	94
Pain in systemic lupus erythematosus: emerging insights and paradigms	93
Immune reset and immune retune: approaching cure?	92
Guiding ILD management in systemic autoimmune rheumatic diseases	92
Dysfunctional UBA1-mutated myeloid cells promote inflammation in VEXAS syndrome	86
Sexual dimorphism in the prevalence, manifestation and outcomes of axial spondyloarthritis	81
Rheumatology in the digital health era: status quo and quo vadis?	79
Targeting the IVD clock to halt degeneration	78
Distinct mucosal endotypes as initiators and drivers of rheumatoid arthritis	78
Which DMARD for ICI-associated arthritis?	78
Phase III trial of telitacicept in SLE	75
A path towards personalized medicine for autoinflammatory and related diseases	73
Publisher Correction: Recent advances in the diagnosis and management of neuropsychiatric lupus	71
Cell-free DNA fragmentation signatures link cancer and autoimmunity	71
Chimeric receptors broaden the therapeutic landscape for autoimmune disease	69
Erosive cargo from synovial fibroblasts	69
ERAP1 and the return of the UPR in ankylosing spondylitis	68
CAR T cells induce drug-free SLE remission	63
Targeting ferroptosis resistance in RA fibroblast-like synoviocytes	62
Insights into IVDD pathogenesis in 2024	62
Macrophage-coated nanocarriers for gouty arthritis	60
Blocking CDK7 attenuates inflammatory arthritis	57
RA risk from occupational inhalation	57
Repolarizing macrophages using antagomirs	57
International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative	57
Innate lymphoid cells in rheumatoid arthritis as mediators of pathology and resolution	56
A critical view of WHO guidelines on management of low back pain	55
Reply to ‘Is cam morphology a cause of osteoarthritis?’	55
All fibroblasts are equal, but some are more equal than others	53
New developments in electronic health record analysis	52
Two sides of management recommendations for psoriatic arthritis	51
A leading role for interferon as a treatment target in Sjögren syndrome	50
TASL has a key role in SLE	50
Platelets as drivers of immunothrombosis in rheumatic diseases	48
Profiling joint tissues at single-cell resolution: advances and insights	46
Fibroblast heterogeneity in 2025	46
Pan American League of Associations for Rheumatology recommendations for the management of axial spondyloarthritis	45
New refinements aim to optimize articular cartilage tissue engineering	45
Unravelling the cellular mechanisms of VEXAS syndrome	44

AhR promotes suppressor cell function in Sjögren syndrome	44
Clarity for the language of race, ethnicity and genetic ancestry in rheumatology	44
Metabolic masqueraders of paediatric and adult rheumatic diseases	43
Fertility, pregnancy and lactation in women with systemic lupus erythematosus	43
Publisher Correction: The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET	43
Piezo1 induces new bone formation in AS	40
Author Correction: International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative	39
Author Correction: Glycobiology of rheumatic diseases	39
Treg cell-inducing nanoparticles show promise for treating OA	38
Pathogenic antibodies target stromal antigens in RA	37
CXCL5 effective in mouse model of SLE	36
APOE in fat pad and synovium contributes to knee OA	36
Sex- and gender-based personalized medicine in rheumatology	35
Rethinking early-stage knee osteoarthritis beyond radiography	35
l-arginine inhibits arthritis and bone loss by reprogramming osteoclast metabolism	35
The obesity–inflammation axis in psoriatic disease: mechanisms and therapeutic strategies	35
Progress made and the road ahead for cancer screening in myositis	35
PDGFR signalling implicated in anti-resorptive effects of sclerostin blockade	34
Location-specific treatment of chronic inflammatory joint disease	34
BiTE therapy for rheumatic diseases	34
STING-driven necroptosis linked to autoinflammatory disease	32
FABP4 exacerbates RA	32
Senotherapeutics suppress disc degeneration	31
Interferon disrupts immune and tissue homeostasis in SLE via CXCL13	31
Critical appraisal of serum urate targets in the management of gout	30
Shifting the SLE management paradigm: challenges and implications	30
Post-transcriptional checkpoints in autoimmunity	29
Diagnostic, prognostic and therapeutic biomarkers in rheumatoid arthritis	29
In vivo CAR-T cell engineering in refractory SLE	28
Parathyroid hormone receptor agonists in the management of osteoporosis	27
Multi-omics reveals distinct MPA subtypes	27
Engineered sialylated IgG1 Fc as a dose-sparing alternative to IVIG	26
COVID-19 linked to rise in anti-MDA5 autoimmunity	26
Notch signalling mediates OA pain in mice	26
Adropin inhibits fibrosis in SSc	26
Complement therapeutics are coming of age in rheumatology	25
State-of-the-art evidence in the treatment of systemic sclerosis	25
Busting the myth of methotrexate chronic hepatotoxicity	25
Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis	24
Citrulline immunity in RA: CD8+ T cells enter the scene	24
The potential contribution of in silico studies to improved treatment of osteoarthritis	24
Identifying fibromyalgia phenotypes based on psychological symptom burden	22
What rheumatology can learn from oncology: a patient’s perspective	22
Treatment of non-systemic juvenile idiopathic arthritis	21
Synovial fluid as a complex molecular pool contributing to knee osteoarthritis	20
Undiagnosed axSpA is prevalent in IBD	20
The PU.1– IL-9 axis in TH9 cells promotes RA	20
Update on the pathophysiology and treatment of primary Sjögren syndrome	20
Glycosylation switch in synovial fibroblasts promotes ECM degradation	20
Bone-modifying drugs slow OA progression	20
The immune health metric as an indicator of health and disease	20
Advances in understanding preclinical rheumatoid arthritis and prospects for prevention	20
Primary care rheumatology: towards sustainable development in health	20
Shedding light onto the immunometabolic effects of glucocorticoids	19
Combination therapy for Behçet uveitis	19
UNC93B1 variants promote SLE via TLR activation	18
Rheumatoid arthritis prevention in arthralgia: fantasy or reality?	18
SIX1 and PAI-1 emerge as therapeutic targets in systemic sclerosis	18
Lupus ABC spearheading a new era of collaboration to advance lupus drug development	18
More than a leaky gut: how gut priming shapes arthritis	17
Advances in viscosupplementation and tribosupplementation for early-stage osteoarthritis therapy	17
Low-frequency and rare genetic variants associated with rheumatoid arthritis risk	16
Reversal of inflammatory priming prevents arthritic flares	16
The role of the immune system in osteoarthritis: mechanisms, challenges and future directions	16
Global epidemiology of spondyloarthritis	15
Reply to: Is classifying SSc-ILD drugs as either immunosuppressive or anti-fibrotic misleading?	15
Phenotypic heterogeneity in psoriatic arthritis: towards tissue pathology-based therapy	15
Disease stratification in GCA and PMR: state of the art and future perspectives	15
Neurodevelopmental comorbidities in juvenile systemic autoimmune and autoinflammatory diseases	15
New guide calls for interdisciplinary approach to TMJ arthritis symptoms	14
Advances in the calculation of minimal important change estimates for patient-reported outcome measures	14
Advances in targeting IL-1 family cytokines for the treatment of inflammatory diseases	14
Current challenges in understanding the epidemiology of calcium pyrophosphate crystal deposition	14
Paediatric glucocorticoid toxicity index: new possibilities in assessment	13
The pathogenesis of gout: molecular insights from genetic, epigenomic and transcriptomic studies	13
PPM1A: TGFβ regulator and therapeutic target in OA	13
Evidence-Based Guideline for the management of osteoporosis in men	13
Pregnancy outcomes improving in axSpA	12
Synovial fibroblast-mediated neovascularization in RA	12
Treat-to-target or treat-to-dissolve strategy to improve gout treatment	12

Macrophages hit a nerve in painful joint venture	12
Age-related mechanisms in the context of rheumatic disease	12
Bridging the gap: combining treat-to-target and difficult-to-treat strategies in the management of rheumatoid arthritis	11
Anti-CD19 CAR T cell therapy promotes skin remodelling in systemic sclerosis	11
Annexin A1 could help prevent periprosthetic bone loss	11
Imaging in inflammatory arthritis: progress towards precision medicine	11
The apprehension of seronegative rheumatoid arthritis	11
Gut T cells help mediate fracture healing	11
Real-world data provide insights into PsA treatment patterns	11
CD38hiCD8+ T cells characterize ICI-mediated arthritis	11
TGFβ priming promotes TNF-induced bone erosion: a promising new target in RA?	10
Optimizing methotrexate withdrawal during COVID vaccination	10
Benralizumab noninferior to mepolizumab for EGPA	10
PJP prophylaxis with rituximab	10
New guideline for integrative approaches to RA management	10
Immunogenic Xist ribonucleoproteins drive sex-biased autoimmunity	10
SGLT2 inhibitors reduce risk of autoimmune disease	9
Treat-to-target in Behçet syndrome	8
HLA-B27 and spondyloarthritis: at the crossroads of innate and adaptive immunity	8
ZEB2 promotes formation of age-related B cells	8
IL-17A and IL-17F in tissue homeostasis, inflammation and regeneration	8
Author Correction: New genes, pathways and therapeutic targets in autoinflammatory diseases	8
Relapsing polychondritis: clinical updates and new differential diagnoses	8
Lupus nephritis-related chronic kidney disease	7
Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone	7
Mechanism of B cell survival in lupus nephritis	7
The clinical benefits of sodium–glucose cotransporter type 2 inhibitors in people with gout	7
JAK inhibitors improve RA pain	7
New screening tool developed to aid diagnosis of axial PsA	7
High risk of autoimmune diseases after COVID-19	7
Delineating inflammatory from non-inflammatory mechanisms for therapy optimization in psoriatic arthritis	7
Reply to: Current classification criteria underestimate the incidence of idiopathic inflammatory myopathies by ignoring subgroups	7
Clonal dominance: mutations in VEXAS syndrome take advantage of inflammation	6
The future of autologous stem cell transplantation in systemic sclerosis	6
Integrin signalling in joint development, homeostasis and osteoarthritis	6
Collagen-binding antibody prevents arthritis	6
Two subsets of TPH cells with distinct functions in RA	6
Limitations of the updated EULAR recommendations for osteoarthritis	6
Inborn errors of immunity and AAV: a complex picture	6
The role of mitochondria in rheumatic diseases	6
Understanding synovial cell diversity in post-traumatic OA	5
ExTH17 cells maintain chronic inflammation in RA	5
ETS1 implicated in polarization of tissue-destructive fibroblasts	5
Sarcoidosis: can tofacitinib slay the dragon?	5
The peculiar features, diversity and impact of citrulline-reactive autoantibodies	5
Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress	5
Sex and gender differences in rheumatology: clinical impact and future directions	5
How muscle influences bone health	5
PD-1, BTLA and TIGIT as therapeutic targets for rheumatic disease	4
Pentose phosphate pathway metabolite restores T cell balance in SLE	4
Hypoxia-modifying hydrogel supports stem cells for joint repair	4
A roadmap for delivering a human musculoskeletal cell atlas	4
Understanding rheumatic disease through continuous cell state analysis	4
A subset of ITGA5+ synovial fibroblasts alter the inflammatory niche in RA	4
Integrin-mediated ILC2 adhesion protects against lupus nephritis	4
A basket genetic trial of the vasculitides	4
PR3 triggers granuloma formation in GPA	4
Advances in cartilage imaging techniques	4
A comprehensive guide for managing the reproductive health of patients with vasculitis	4
Joint location matters for TNF inhibitor treatment in PsA	4
Reply to ‘Inborn errors of immunity and AAV: a complex picture’	4
Lactylation of SOD1 promotes oxidative damage in IVDD	4
Sex and gender matter for TNF inhibitor therapy in RA	4
Reply to: Hypothetical model ignores many important pathophysiologic mechanisms in fibromyalgia	4
Publisher Correction: IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting	4
T cells in Sjögren disease	4
Secukinumab shows diverging efficacy in PMR and GCA	4
Fibroblasts in immune responses, inflammatory diseases and therapeutic implications	4
Novel approach mitigates immunogenicity of uricase treatment	4
Breaking research silos to achieve equitable precision medicine in rheumatology	4
The therapeutic potential of immunoengineering for systemic autoimmunity	4
New evidence for the ‘cusp theory’ to explain HLA associations in SLE	4
VEXAS syndrome more common than originally thought?	4
Is X chromosome inactivation a cause or effect of SLE?	4
Dapirolizumab pegol improves SLE disease activity in phase III trial	3
A safe and effective treatment for MAS	3
CD142+ synovial fibroblasts attack the meniscus in knee RA	3
SARS-CoV-2 vaccine safe for young patients	3
Advancements and challenges in CAR T cell therapy in autoimmune diseases	3
Mannosylation is a cause and target in lupus nephritis	3
Pre-RA autoantibodies recognize arthritogenic gut bacterium	3
Targeting anti-PAD4 autoantibodies in RA	3
Molecular biomarker approaches to prevention of post-traumatic osteoarthritis	3
Global epidemiology of rheumatoid arthritis	3
Non-depleting anti-CD19 B cell inhibition	3
Insights into juvenile myositis via engineered muscle	3
How does citrullination contribute to RA autoantibody development?	3
Mito+ RBCs prompt IFN and IL-1β release by SLE monocytes	3
Sex- and gender-related differences in psoriatic arthritis	3
Imaging inflammation with leukocyte-targeted PET tracers	3
Targeted NOD2 sequencing uncovers JIA misdiagnosis	3
Antigen-specific immunotherapies for autoimmune disease	3
Rethinking antiphospholipid syndrome to guide future management and research	3
CXCL7 promotes bone erosion in RA	3
Treatment of lupus nephritis: consensus, evidence and perspectives	3